PHARMA NEWS - Click here to see all recent News about Pharma Industry @ one Place - "D2"

Roche acquires respiratory therapy firm at $8.3 bn - InterMune's lead medicine pirfenidone is approved for idiopathic pulmonary fibrosis in the EU and Canada - Singapore: Global biopharmaceutical company, Roche, has acquired InterMune, a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and fibrotic diseases, at USD8.3

from CLINI INDIA http://ift.tt/1qQ37II

via IFTTT